The Filing Desk

Intellia Therapeutics vs Vir Biotechnology

Intellia Therapeutics NTLA · Vir Biotechnology VIR · Biotechnology

Vir Biotechnology reported revenue of $69 million in fiscal 2025, about the same as Intellia Therapeutics' $68 million in fiscal 2025. Intellia Therapeutics' revenue grew 16.9% in its latest year, and Vir Biotechnology's fell 7.6%. Intellia Therapeutics had an operating margin of -651.7%, against -699.2% at Vir Biotechnology. Free cash flow was −$396 million at Intellia Therapeutics and −$397 million at Vir Biotechnology.

Side by side

Intellia TherapeuticsVir Biotechnology
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$68M$69M
Revenue growth16.9%−7.6%
Revenue growth a year, last 5 years3.1%−2.1%
Gross margin—100.0%
Operating margin−651.7%−699.2%
Net margin−609.9%−638.9%
Free cash flow−$396M−$397M
Free cash flow margin−585.0%−578.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count9.6%1.7%
Last close$9.70$9.96
P/E at the last close——
Insider trades, last 12 monthsbought $1.4 million, sold $2.1 millionsold $8.2 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Intellia TherapeuticsVir Biotechnology
Operating margin
Percent of revenue
Intellia TherapeuticsVir Biotechnology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Intellia TherapeuticsVir Biotechnology

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Intellia Therapeutics and Vir Biotechnology pages.